Health Canada Approves Mounjaro for Cardiovascular Risk Reduction
11/18/2026
Impact: 55
Healthcare
Health Canada granted Eli Lilly Canada a Notice of Compliance for Mounjaro (tirzepatide) to reduce major adverse cardiovascular events—including cardiovascular death, non-fatal heart attack, and non-fatal stroke—in adults with type 2 diabetes and established cardiovascular disease. The approval is based on clinical data showing improved cardiovascular outcomes in this population. Lilly said the drug’s safety profile was consistent with its established profile, with gastrointestinal events most common; the article reported no financial figures or stock-price impact.
AI summary, not financial advice
Share: